QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.